"10.1371_journal.pone.0059767","plos one","2013-03-29T00:00:00Z","Camille Lécuroux; Isabelle Girault; Antoine Chéret; Pierre Versmisse; Georges Nembot; Laurence Meyer; Christine Rouzioux; Gianfranco Pancino; Alain Venet; Asier Sáez-Cirión; ANRS 147 OPTIPRIM clinical trial","INSERM, U1012, Le Kremlin Bicêtre, France; Hôpital Gustave Dron, Service de Maladies Infectieuses et du voyageur, Tourcoing, France; EA 3620, Université Paris-Descartes, Sorbonne Paris Cité, Paris, France; Institut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France; INSERM U1018, Université Paris-Sud 11, Le Kremlin Bicêtre, France; AP-HP, Hôpital de Bicêtre, Département dépidémiologie, Le Kremlin Bicêtre, France; AP-HP, CHU Necker-Enfants Malades, Laboratoire de Virologie, Paris, France","Critical reviewing of manuscript: CL IG AC PV GN LM CR GP AV AS-C. Conceived and designed the experiments: AC CR GP AV AS-C. Performed the experiments: CL IG PV. Analyzed the data: CL IG LM GP AV AS-C. Contributed reagents/materials/analysis tools: GN. Wrote the paper: CL AS-C.","The OPTIPRIM clinical trial was funded by the ANRS (French National Agency for Research on AIDS and Viral Hepatitis). However, ANRS received financial support from MSD, Janssen, ViiV Healthcare and Gilead to complement funding concerning this trial. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Camille Lécuroux","CL",11,TRUE,5,3,6,2,TRUE,TRUE,FALSE,0,NA,FALSE
